Columbia University

Technology Ventures

Featured Funding Opportunities

In support of its mission to facilitate the transfer of inventions from academic research labs to the market, CTV publicizes funding opportunities that may be relevant to Columbia inventors as they conduct research and develop new technologies. For additional lists of funding opportunities, refer to these resources:

For further assistance with grant applications, see CTV's collection of IP and Entrepreneurship Language for Grant Applications.

Upcoming Opportunities

right
Deadline: 
Friday, February 5, 2021 - 5:00pm

Bristol Myers Squibb seeks proposals on topics designed to address questions developed by its Immuno-Oncology and Cell Therapy (IOCT) Thematic Research Center.

Areas of interest:

  • Approaches to normalize the tumor vasculature to improve cell therapy/T cell engagers/NK cell engager therapies
  • Novel technology which can support cell therapy target identification for solid tumors
  • Targeting T cell metabolism pathways to improve T cell fitness for cell therapy in vivo

RFP guidelines:

Past Funding Opportunities

right
Deadline: 
Monday, December 14, 2020 - 5:00pm

Why did Atomwise create this award?
The goal of this program is to broaden the pool of scientists pursuing drug discovery. To advance this goal, Atomwise will award researchers with a customized virtual screen using cutting-edge Artificial Intelligence (AI) technology, approximately 72 chemical compounds for physical screening, and technical support from medicinal chemists and computational biologists.

right
Deadline: 
Friday, November 13, 2020 - 5:00pm

 

 

Emerson Collective seeks to fund collaborative clinical research focused on populations with unequal burdens of colorectal cancer (CRC) by exploring the association between molecular characteristics such as tumor mutation and clinical characteristics such as disease stage, recurrence rate, and overall survival. 

right
Deadline: 
Saturday, October 31, 2020 - 5:00pm

 

 

Cyclica is an AI-based drug discovery company that has developed a structure-based, AI-augmented in silico drug discovery platform. CAPP is an opportunity for academic investigators to apply for in-kind access to Cyclica’s drug development platforms. The program offers two types of awards: 

Ligand Design Award: to generate novel compounds for your target of interest

right
Deadline: 
Friday, November 20, 2020 - 5:00pm

Are you interested in bringing your life science innovations to life? The Columbia Life Science Accelerator programs help translate cutting-edge faculty-led university research out of the lab through project funding, education, and support for interdisciplinary teams working to advance innovative ideas with the potential to positively impact health outcomes.

The 2020-2021 cycle focuses on:

Therapeutics/Drug Development

right
Deadline: 
Monday, July 27, 2020 - 5:00pm

Columbia University, New York University, and Takeda Pharmaceuticals have formed a collaborative research alliance to initiate and advance gastroenterology (GI) research programs with high potential to impact the development of new therapeutics for patients with GI disorders. Takeda is a global, value-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.

right
Deadline: 
Monday, September 21, 2020 - 5:00pm

Pfizer’s Centers for Therapeutic Innovation, or CTI, is a unique joint drug discovery model focused on collaborating with leading academic medical centers to translate and transform concepts into breakthroughs that change patients’ lives.

right
Deadline: 
Thursday, December 31, 2020 - 3:15pm
Click here for a list of of COVID-19 Funding Opportunities compiled by Columbia Research.
right
Deadline: 
Monday, May 18, 2020 - 5:00pm
Overview:
The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute® (HDI) have partnered to accelerate the translation of academic discoveries into medicines for treating, preventing, or curing patients with Alzheimer’s disease and related dementias.

Pages